This website uses cookies

This websites contains videos from YouTube. This company uses cookies (third party cookies). If you do not want them to use these cookies, you can indicate so here. However, this does mean that you will not be able to watch videos on this website. We also make use of our own cookies in order to improve our website. We don't share our data with other parties. Which cookies are involved?

This website uses cookies to enable video and to improve the user experience. If you do not want to accept these cookies, indicate so here. Which cookies are involved?

Ga direct naar de inhoud, het hoofdmenu, het servicemenu of het zoekveld.

Back to overview

Sabine Linn group

SabineLinn.jpg

Sabine Linn

Groupleader

Personal details

Experience

Dr. Sabine Linn is a professor of translational oncology focusing on breast cancer at Utrecht University, The Netherlands. Linn received her medical degree (1991, cum laude) at the State University Leiden, The Netherlands, and her internal medicine board certification (2000) at the University Medical Center Utrecht, The Netherlands. She earned her PhD (1998) on the subject of multidrug resistance in solid tumors from the Free University of Amsterdam under supervision of prof. Dr H.M. Pinedo.

She was awarded a Dutch Cancer Society Research Fellowship in 2000 and developed two conditional knock-out mouse models, one for non-small cell lung cancer and one for small cell lung cancer, respectively, in close collaboration with Dr Ralph Meuwissen in the laboratory of prof. Dr A.J. Berns at the Netherlands Cancer Institute, Amsterdam, The Netherlands. From 2001 to 2002 she was a postdoctoral research fellow in the laboratories of prof. Dr P.O. Brown, and prof. Dr M. van de Rijn, at Stanford University Medical School, Stanford, CA, where she contributed to the development of a molecular classification for soft tissue sarcomas. She returned to the Netherlands Cancer Institute in Amsterdam, where she earned her medical oncology certification (2002-2005) and became a senior staff member of the Division of Medical Oncology (2003).

Since 2005 she has also been a group leader at the Division of Molecular Pathology at the Netherlands Cancer Institute where she and her research group focus on the molecular dissection of breast cancer by differential drug sensitivity. To further develop this research line Dr. Linn was awarded a Dutch Cancer Society Clinical Research Award in 2006. From 2008-2012, Dr Linn served as chair of the Working Group on (neo)adjuvant systemic therapy of the Dutch Breast Cancer Trialists' Group (BOOG).

Share this page